A Prospective, Multicenter, Randomized, Comparative Clinical Study to Compare the Safety and Effectiveness of Two Vertebral Compression Fracture (VCF) Reduction Techniques: the SpineJack® and the KyphX Xpander® Inflatable Bone Tamp
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 152
- 试验地点
- 13
- 主要终点
- Proportion of Participants With Study Success
研究概览
简要总结
The purpose of this study is to compare the safety and effectiveness of the SpineJack® with the Kyphx Xpander® Inflatable Bone Tamp and support a non-inferiority finding for the use of SpineJack® VCF treatment system versus Balloon Kyphoplasty.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 50 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or Female with at least 50 years of age
- •1 painful VCF which at least meet all following criteria:
- •Fracture due to diagnosed or presumed underlying osteoporosis
- •VCF between T7 and L3
- •Fracture age <3 months
- •VCF shows loss of height in the anterior, mid or posterior third of the VB from estimated pre-fracture configuration of at least 15% but not more than 40% based on X-Ray at baseline
- •The Index fracture is acute or persistent (not healed), as demonstrated by T2 weighted STIR MRI (or bone scan if patient is contraindicated for MRI)
- •Patient has failed conservative medical therapy, defined as either having a VAS back pain score of ≥50 mm at 6 weeks after initiation of fracture care or a VAS back pain score of ≥70mm at 2 weeks after initiation of fracture care
- •Investigator believes target VB is suitable for SpineJack procedure and Balloon kyphoplasty (e.g., appropriate pedicle diameter) assessed on CT scan pre op
- •Patient has an Oswestry Disability Index (ODI) score of ≥ 30/100
- •Patient is mentally capable and willing to sign a study specific informed consent as documentation of the informed consent process prior to any study procedures
- •The patient is willing and able to comply with all study requirements including follow-up visits and radiographic assessments.
排除标准
- •Target VCF due to underlying or suspected tumor
- •Target VCF due to high-energy trauma
- •Target VCF is diagnosed as an osteonecrotic fracture
- •Segmental kyphosis of target VB of >30°
- •Any prior surgical treatment for a vertebral body compression fracture or other surgical procedure on target VB or adjacent level
- •The patient has uncontrolled diabetes
- •Pre-existing or clinically unstable neurologic deficit
- •The patient has spinal canal compromise causing clinical manifestations of cord, neural foramen, or nerve root compression at the level to be treated
- •Any physical exam evidence of myelopathy or radiculopathy
- •The patient has pain based on clinical diagnosis of herniated nucleus pulposus or severe spinal stenosis (progressive weakness or paralysis)
- •Patient not able to walk without assistance prior to fracture
- •Any radiographic evidence of pedicle fracture visible on CT scan pre op
- •Spondylolisthesis >Grade 1 at target VB
- •Any underlying systemic bone disease other than osteoporosis (e.g., osteomalacia, osteogenesis imperfect, Paget's disease, etc.)
- •A medical contraindication to spinal surgery and/or general anesthesia, such as coagulopathy and/or taking warfarin (Coumadin) or other anticoagulant on regular basis for coagulopathy (with a threshold for normal being INR≤1.5, PTT within lab normal range, and platelet count > 100,000)
- •Pain due to any other condition that requires daily narcotic medication
- •Disabling back pain due to causes other than acute fracture
- •History of intolerance or allergic reaction to titanium or acrylic compounds
- •Active systemic or local infection at baseline
- •Body mass index >40
- •Severe cardiopulmonary deficiencies
- •Any other medical illness or condition that, in the investigator's opinion, is likely to impair long-term follow-up (e.g., cancer) or greatly increase the risk of surgery including but not limited to patients with contraindications for general anesthesia (surgeon expertise)
- •Any evidence of alcohol or drug abuse
- •The patient has uncontrolled psychiatric illness or severe dementia
- •The patient is currently on anti-cancer therapy or anti-HIV therapy
- •Patient's life expectancy is less than the study duration or undergoing palliative care
- •Participating in any other investigational study
- •The patient is on long-term steroid therapy (steroid dose ≥ 30 mg /day for > 3 months)
- •The patient is known to be involved in medical litigation including Workmen's Compensation
- •Patient with contraindication for MRI
- •The patient is pregnant or considering getting pregnant during study participation.
研究组 & 干预措施
Balloon Kyphoplasty
VCF treatment system Vertebral fracture surgery
干预措施: Balloon Kyphoplasty (Procedure)
SpineJack® system
VCF treatment system Vertebral fracture surgery
干预措施: Vertebral fracture surgery SpineJack® (Device)
结局指标
主要结局
Proportion of Participants With Study Success
时间窗: 12 month post-op
The primary composite endpoint defines a successful subject if the following components are satisfied (safety and effectiveness): 1. Reduction in VCF fracture-related pain at 12 months from baseline as measured by a 100 mm VAS scale (reduction of pain at 12 months by \> 20 mm) AND, 2. Maintenance or improvement in function at 12 months from baseline as measured by the 100 point Oswestry Disability Index (ODI) AND, 3. Absence of device-related serious adverse events, defined as device-related adverse events (device migration, recollapse, protrusion) or symptomatic cement extravasation requiring surgical re-intervention or retreatment at the index level, including revision, removal, reoperation, and/or supplemental fixation.
次要结局
未报告次要终点
